Vimarsana
Biggest News Aggregation in the World

Rezolute Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Rezolute Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Rezolute Inc Today - Breaking & Trending Today

Rezolute, Inc. (NASDAQ:RZLT) Sees Large Increase in Short Interest - Vimarsana News

Rezolute, Inc. (NASDAQ:RZLT) Sees Large Increase in Short Interest

Rezolute, Inc. (NASDAQ:RZLT – Get Free Report) was the recipient of a large growth in short interest during the month of May. As of May 31st, there was short interest totalling 814,600 shares, a growth of 162.0% from the May 15th total of 310,900 shares. Based on an average daily trading volume, of 571,100 shares, […]

Rezolute, Inc. (NASDAQ:RZLT) Insider Brian Kenneth Roberts Purchases 7,500 Shares - Vimarsana News

Rezolute, Inc. (NASDAQ:RZLT) Insider Brian Kenneth Roberts Purchases 7,500 Shares

Rezolute, Inc. (NASDAQ:RZLT – Get Free Report) insider Brian Kenneth Roberts bought 7,500 shares of the company’s stock in a transaction on Thursday, May 23rd. The stock was bought at an average cost of $2.69 per share, with a total value of $20,175.00. Following the completion of the purchase, the insider now owns 50,052 shares […]

Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME) - Rezolute (NASDAQ:RZLT) - Vimarsana News

Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME) - Rezolute (NASDAQ:RZLT)

Met primary study endpoints: good safety profile and reduction in central subfield thickness (CST) First oral therapy to demonstrate reduction in macular edema; supports potential for early disease intervention Virtual

Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME) - Vimarsana News

Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME)

Met primary study endpoints: good safety profile and reduction in central subfield thickness First oral therapy to demonstrate reduction in macular edema; supports potential for early disease...

Rezolute's (RZLT) Buy Rating Reaffirmed at HC Wainwright - Vimarsana News

Rezolute's (RZLT) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of Rezolute (NASDAQ:RZLT – Free Report) in a research note released on Thursday, Benzinga reports. They currently have a $14.00 price target on the stock. A number of other analysts have also recently weighed in on the stock. JMP Securities reissued a market outperform rating and set […]

Source: wkrb13.com